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Abstract Osteoporosis and osteomalacia are, to date,
among the most common metabolic diseases in the world.
Lately, an association between metabolic bone diseases and
chronic liver disease has been increasingly reported,
inducing many authors to create a new nosographic entity
known as ‘hepatic osteodystrophy.’ The importance of
such a condition is further increased by the morbidity of
these two diseases, which greatly reduce the quality of life
because of frequent fractures, especially vertebral and
femoral neck ones. For this reason, early identification of
high-risk patients should be routinely performed by mea-
suring bone mass density. The explanation for the associ-
ation between bone diseases and chronic liver disease is
still uncertain, and involves many factors: from hypogo-
nadism to use of corticosteroid drugs, from genetic factors
to interferon therapy. To date, few studies have been
conducted, and all with a small number of patients to
establish definitive conclusions about the possible treat-
ment, but some evidence is beginning to emerge about the
safety and efficacy of bisphosphonates.
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Introduction
Metabolic bone diseases, i.e., osteomalacia and osteopo-
rosis, are frequent complications of patients affected with
chronic liver disease (CLD), to the point that some authors
have coined the term ‘hepatic osteodystrophy’ to mean the
complex of structural and metabolic changes of bone in
patients with both cirrhotic and non-cirrhotic CLD. Among
these, osteoporosis is particularly important because more
frequent than osteomalacia, and often responsible for
fractures, which, although most often asymptomatic, con-
tribute, in any case, to morbidity and reduction of the
quality of life. Unlike vertebral fractures, femoral neck and
extremities ones, symptomatic by definition, are less fre-
quent in these patients, because, even in subjects not suf-
fering from CLD, they occur about 10 years after the
former, that is, beyond the life expectancy of many patients
with CLD [1].
Osteomalacy and chronic liver diseases
Osteomalacia is a metabolic osteopathy characterized by a
reduced amount of bone mineral content due to lack of
mineralization. This osteopathy, which potentially can be
found in several pathological conditions, is usually caused
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by reduced availability or abnormal metabolism of vitamin
D. Osteomalacia, although in the past reported in more than
60% of patients with primary biliary cirrhosis (PBC), is
currently demonstrated in only a small percentage of
patients with CLD, especially in advanced cholestatic ones,
with severe intestinal malabsorption, and in geographical
areas with limited sunlight exposure. The changes in
prevalence of this disease, occurring in recent decades,
reflect, probably, the use of different diagnostic criteria,
errors in selection of patients included in trials, and nutri-
tional improvements. However, the gold standard for the
diagnosis of osteomalacia is still considered to be bone
biopsy, because not all patients with low serum levels of
vitamin D suffer from this metabolic disease [2].
As a matter of fact, vitamin D includes a group of fat-
soluble prohormones (Fig. 1). The group includes two
compounds with very similar biological activity: cholecal-
ciferol (D3), derived from cholesterol and synthesized in
animals, and ergocalciferol (D2), of vegetable origin. In
humans, vitamin D3 is produced by ultraviolet irradiation of
the skin from a precursor, 7-dehydrocholesterol, which is in
the subcorneal layer. Adequate exposure to sunlight grants
endogenous production of cholecalciferol able to satisfy the
needs of the whole organism; hence, dietary supplement is
not necessary. The digestive tract absorption of vitamin D
from food sources, animal (D3) or vegetable (D2), follows
similar processes employed by other fat-soluble vitamins.
Vitamin D is incorporated into the micelles, formed by
interaction between hydrolyzed lipids and bile, cross the
intestinal epithelium, and finally is incorporated in chylo-
microns, which, in turn, enter the lymphatic circulation. In
various tissues, especially in the liver, hydroxylation
of cholecalciferol produce 25-hydroxycholecalciferol
(25-OHD), which then passes into the general circulation, and
interacts with a specific transport protein (vitamin D bind-
ing protein, DBP), synthesized by the liver. In the kidney,
the 25-OHD may undergo two different hydroxylation
reactions, caused by different hydroxylase, 1-hydroxylase
and 24-hydroxylase, generating, respectively, 1,25-dihy-
droxycholecalciferol (1,25-OHD), the active form of vita-
min D, and 24,25-dihydroxycholecalciferol (24,25-OHD),
the inactive form. As the liver is involved in the production
of bile, vitamin D3 absorption (fat-soluble vitamin) and
blood transport, through the DBP synthesis, and
25-hydroxylation, which produces 25-OHD, it would be
easy to assume a high prevalence of osteomalacia in
patients suffering from CLD, not confirmed, as mentioned
above, in more recent years. In fact, adults obtain most of
their vitamin D3 from cutaneous photoconversion of
7-dehydrocholesterol, and patients with cholestasis seem to
have normal skin photoconversion processes. In addition,
intestinal vitamin D absorption is altered only in the
presence of a severe cholestasis. The succeeding 25-hepatic
vitamin D3 hydroxylation has so far been little studied in
human, but in experimental animals, with severe chole-
stasis, does not seem impaired. In any case, about 2/3 of
patients with liver cirrhosis and 96% of terminal cirrhotic
patients waiting for liver transplant have low serum levels
of vitamin D3, even if without any demonstrated osteo-
malacia. However, vitamin D derivatives may be involved
in cell proliferation, differentiation, and immunomodula-
tion. Vitamin D inhibits some types of matrix
Fig. 1 Vitamin D metabolism
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metalloproteinases (MMP, a family of zinc-dependent
endoproteinases that are involved in the degradation of
extracellular matrix components) and induces their inhib-
itors. Finally, suppression of fibroblast proliferation and
collagen production are other vitamin D effects. These data
are relevant to CLD, and vitamin D deficiency can lead to
progression of hepatic fibrosis. Therefore, in view of the
increasingly recognized beneficial effects of adequate
levels of vitamin D, measurement of 25-OHD levels and its
replacement may be considered as a part of the overall
management of patients with CLD [3].
Osteoporosis and chronic liver diseases
Osteoporosis is defined as a value of bone mineral density
(BMD), measured by dual-energy X-ray absorptiometry
(DEXA), \2.5 standard deviations below the average of a
young adult population control bone mass peak (corre-
sponding to the normal bone mass peak) (T score \-2.5),
whereas osteopenia is defined as T score values between
-1 and -2.5. ‘Normal’ is a BMD with a T score better than
-1. Although the risk of fractures increases gradually with
decreasing BMD, many other clinical risk factors are
important, all independent from BMD, such as advanced
age, menopause, body mass index (BMI) \19 kg/m2
(expression of malnutrition or poor nutrition), alcohol
intake [3 U/day (1 U = 8 g alcohol), smoking, oral cor-
ticosteroid therapy [5 mg/day of prednisone for at least
3 months, previous fragility fractures, and maternal history
of hip fracture. The most important of these is surely
represented by previous fragility fractures. Once a vertebral
fracture occurs, the risk of further vertebral fracture
increases by 10 times, while risk of a subsequent hip
fracture increases by 2.3 times [4].
Osteoporosis occurs in patients with CLD, affects
mainly trabecular bone, and has been characterized by low
bone turnover, with reduced osteoblast function, and low
serum osteocalcin levels. However, there is a certain het-
erogeneity regarding the prevalence of osteoporosis in
CLD patients, which depends on patient selection, liver
disease etiology and stage, and additional risk factors for
osteoporosis. Actually, most studies have been focused on
bone disease in chronic cholestatic liver disease, mainly in
patients with PBC, and in bone disease before and after
liver transplantation. In contrast, few studies evaluate bone
disorders in other CLD, such as hereditary hemochroma-
tosis, viral hepatitis, and alcoholic liver disease. In addi-
tion, many osteoporosis additional risk factors, including
hypogonadism, malnutrition, excessive alcohol intake and
use of corticosteroid drugs (i.e., treatment of autoimmune
liver diseases, as PBC and primary sclerosing cholangitis
(PSC),) may be found in patients affected with CLD.
Moreover, many patients with PBC are, by definition,
postmenopausal women, sometimes also affected with
inflammatory bowel diseases, which significantly increase
osteoporosis risk. It is still questionable whether liver cir-
rhosis and cholestasis are, themselves, independent risk
factors for osteoporosis, since this topic has been not yet
completely studied [5].
Pathophysiology of osteoporosis in chronic liver
diseases
The amount of bone mass depends on the balance between
two opposite processes: bone resorption, originated by
osteoclasts, and bone formation, induced by osteoblasts. As
a consequence, if resorption exceeds formation, there is a
negative balance, which results in bone loss and osteopo-
rosis. The mechanisms resulting in osteoporosis patho-
genesis in liver disease have not been completely
elucidated. Some studies indicate an increased bone
resorption, although most point towards a decreased bone
formation. Indeed, impaired osteoblast function, resulting
in lower mean wall thickness and a defect in matrix syn-
thesis, as well as a low bone formation rate, that affects,
mainly, trabecular one, have been reported. These data are
consistent with the decreased serum levels of osteocalcin, a
biochemical marker of bone formation [6].
Probably, the main role in the pathophysiology of
osteoporosis in these conditions is played by leading
pathogenic factors, such as gender and hormone changes,
i.e., hypogonadism, which is frequent in patients with
hereditary hemochromatosis, cirrhosis and alcoholic liver
disease. However, biological mechanisms underlying
osteoporosis of patients with CLD are complex, and now-
adays only slightly understood, and include, perhaps, also
genetic and acquired factors.
Hypogonadism seems to play a particularly important
role among osteodystrophy pathogenic mechanisms in
CLD. Low-free testosterone levels as well as levels of
estrogens that have a relative increase point to hypogo-
nadism in men with liver cirrhosis. Alteration of sensitivity
of the hypothalamic–pituitary–gonadal axis seems to be, at
least in part, responsible for the reduction of free testos-
terone levels, depending on the lower gonadal production.
As a matter of fact, patients affected with liver cirrhosis
show FSH and LH levels only slightly increased, but cer-
tainly not so high as expected because of a severe lack of
circulating sex hormones. As testosterone is metabolized to
estrogen, a long duration of hypogonadism in men is often
associated with a reduction in circulating estrogens, and
consequent reduced bone turnover, with decreased osteo-
synthesis [7]. Since these endocrine alterations described
above play a heavy clinical role in male, it is clear that
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most studies on this aspect have been conducted in cir-
rhotic males. However, limited data, obtained in female
patients with cirrhosis, show that levels of testosterone,
FSH and LH levels are significantly reduced. The link
between CLD and osteoporosis is emphasized by the hor-
monal changes that can lead to secondary amenorrhea in
young women affected with liver cirrhosis [8]. Among
genetic factors, it must be consider collagen type Ia1,
vitamin D receptor (VDR), estrogen receptor and low
density lipoprotein receptor-binding protein 5 (LRP5)
genes, but their polymorphism has not yet been associated
with an increased, specific fracture risk, even in patients
without CLD [9].
As mentioned above, a possible acquired dissociation
between bone formation and resorption may explain bone
loss, subsequent to bone mass peak overtaking. Increase in
osteoclastic activity, resulting in enhanced bone resorption,
is mediated by osteoclastogenic pro-inflammatory cyto-
kines, such as IL-1 and TNF, often involved both in hepatic
inflammation and fibrosis. Lately, receptor activator of NF-
jB (RANK) protein and RANK ligand (RANKL), in
addition to osteoprotegerin (OPG), have been involved in
osteoclastic bone resorption mechanisms in patients with no
hepatic osteoporosis, while assessment of their involvement
in CLD patients has, so far, produced contradictory results
[10].
Contrariwise, reduction of bone formation, observed in
patients with CLD, is associated with low serum levels of
IGF-1, a protein, primarily synthesized in the liver, known
to be involved in bone remodeling and maintenance of
bone mass, as a trophic and proliferative factor for osteo-
blasts. A clear association between IGF-1 serum levels and
osteoporosis, in CLD in humans, has not been, yet clearly
demonstrated [11].
Vitamin K is also involved in bone metabolism, by
carboxylation of glutamic acid residues of bone proteins,
such as osteocalcin, but there are no literature data about
vitamin K deficiency role in osteoporosis pathogenesis in
hepatic diseases [12].
Although indirect (unconjugated) bilirubin inhibits the
activity of osteoblasts and their function, both in vitro and in
vivo studies, conducted in animal models and patients with
CLD, show no correlation between total, direct and indirect
bilirubin levels and BMD [13]. Recent experiments dem-
onstrate that lithocholic acid (LCA), a monohydroxylated
secondary bile acid, synthesized mainly from the intestinal
bacterial 7-dehydroxylation of chenodeoxycholic acid, has
deleterious effects on human osteoblasts, both in relation to
their viability and regarding the potential damaging effects
of LCA on vitamin D pathways, through ligation to VDR.
Actually, significant decreased osteoblast viability is dem-
onstrated when adding LCA to osteoblasts culture media.
This detrimental effect of LCA on osteoblasts viability is
decreased or completely abolished by adding proteins, i.e.,
human albumin, to the culture media. These results can be
explained by the binding capacity of albumin, which may
have, partially or completely, absorbed or sequestered free
LCA, and therefore, decreases its detrimental effect on cell
viability. Therefore, this observation is in accordance with
the well-known capacity of albumin as a bile acid trans-
porter, and it could be proposed that the amount of circu-
lating albumin is one of the critical factors to explain the
harmful effects on bone of circulating bile acids retained
in patients with chronic cholestasis, data which are in
agreement with the higher prevalence of osteoporosis and
bone fractures observed in patients with PBC and severe
cholestasis. As a matter of fact, a lower serum albumin
concentration may be detected in osteoporotic patients
affected with PBC with osteoporosis than in not osteoporotic
ones. In addition, LCA interaction with VDR modifies
expression of VDR-mediated genes, such as vitamin D
24-hydroxylase (CYP24A), bone gamma-carboxyglutamate
protein (BGLAP), and receptor activator for NFjB ligand
(RANKL, TNFSF11), used as indicators of vitamin D
catabolism, osteoblast maturation, and regulation of osteo-
clast differentiation and activation, respectively [14].
Prevalence of osteoporosis and fractures in chronic
liver diseases
There is some heterogeneity regarding prevalence of
osteoporosis and fractures in patients affected with CLD,
which partly depends on patient selection and diagnostic
criteria. Approximately 30% of patients with liver disease
have osteoporosis, with a higher prevalence in patients
affected with PBC, the latter having two additional risk
factors: chronic cholestasis and female gender. The prev-
alence of fractures in patients with liver disease ranges
from 7 to 35%. Fractures are more prevalent in postmen-
opausal women than in young women and men and in
patients with autoimmune hepatitis treated with cortico-
steroid drugs [1].
Biliary diseases: primary biliary cirrhosis and primary
sclerosing cholangitis
An etiologic relationship between PBC and osteoporosis is
still very controversial, because patients suffering from this
disease are classically postmenopausal women, themselves,
therefore, at high risk of osteoporosis, sometimes also
affected with inflammatory bowel diseases, another con-
dition that significantly increases osteoporosis risk. In
patients with PBC, osteoporosis has been recently reported
to be up to 37% in a series of 185 Spanish female patients,
the lumbar spine being more severely affected than the
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femoral neck. The prevalences of vertebral, non-vertebral,
and overall fractures are 11.2, 12.2, 20.8%, respectively.
Non-vertebral fractures included mostly wrist fractures,
followed by lower limb fractures; only one patient had a
hip fracture. Vertebral fractures are associated with oste-
openia and osteoporosis, with a T score lower than -1.5,
whereas osteopenia and osteoporosis are associated with
the severity of liver damage. The clear-cut correlation
between vertebral fracture and a T score lower than -1.5,
observed in these patients may indicate that this densito-
metric measurement is a useful criteria for prescribing
agents to prevent further loss of bone mass and development
of new fractures [15]. Similarly, Menon et al. [16] found
that as many as 20% of PBC patients, in a large series from
the Mayo Clinic, have osteoporosis. In both studies, oste-
oporosis is more frequent in PBC than in healthy control
women. Mounach et al. evaluating a series of 33 women
with PBC and 66 healthy control subjects, find the mean
T score to be lower in the PBC group as compared to healthy
controls, with a significant statistical difference both for
lumbar spine and total hip involvement. The prevalence of
osteoporosis is 51.5% in the PBC group versus 22.7% in
healthy controls, with a statistically significant difference.
A positive relationship between BMD, values of BMI and
25-OHD has been highlighted, whereas a negative one has
been reported for menopausal status, duration of disease,
and parathyroid hormone (PTH) levels [17].
A recent UK study confirms a substantially increased
osteoporosis and fracture risk in this particular group of
patients when compared with age-matched healthy con-
trols, with a prevalence of 43% for osteoporosis and 22%
for fractures. There are approximately twofold relative
increases in the risk of any fracture, hip fracture and ulna/
radius fracture for the PBC cohort compared with general
population [18].
All these observations are of interest, because as other
studies suggest, osteoporosis is not a specific complication
of PBC, its frequency being the one expected in a popu-
lation of middle-aged postmenopausal women [19].
In contrast, nowadays, it seems that liver damage may
play a relevant role, resulting in bone loss. Two recent
studies propose a role for the severity and duration of
cholestasis in the development of osteoporosis. Thus, a
higher Mayo risk score, calculating the severity of PBC,
and advanced histological stage of the liver disease, in
addition to advanced age and lower BMI, are the inde-
pendent risk factors for osteoporosis in a series of women
with PBC [20]. Similarly, Menon et al. report that age,
BMI, advanced stage of the disease, and history of frac-
tures are the only independent indicators of osteoporosis.
Furthermore, the serum bilirubin level is the only inde-
pendently associated variable with the rate of bone loss
over time [16]. In these studies, the authors also demon-
strate that agents, such as prednisone and budesonide, used
for the treatment of the liver disease, may also affect bone
mass, and that the risk for fracture, in PBC, is associated
mainly with low bone mass, and, indirectly, through this
condition, with the severity and duration of liver disease.
Unlike PBC, PSC occurs at a younger age, and affects
mainly male subjects. Most patients with PSC also have
inflammatory bowel disease, which significantly increases
the risk of developing osteoporosis, particularly Crohn’s
disease. This risk is even greater in patients with IBD
treated with corticosteroids. The prevalence of osteoporosis
in PSC stands at 20.3%, with wide variability among the
studies, while risk of fracture, approximately 15%, corre-
lates with increasing age, more advanced biliary disease
and duration of a coexisting and associated inflammatory
bowel disease [21].
Another even more recent evaluating a cohort of 237
patients with PSC, demonstrates that osteoporosis affects
15% of patients and occurs 23.8-fold more frequently in
those with PSC than expected from a matched population.
Age (54 years or older), low BMI and inflammatory bowel
disease duration positively correlates with the presence of
osteoporosis. Osteoporosis can be detected in 75% of
patients with all three risk factors, but in only 3.1% of those
without all of them. Patients with PSC lose 1% of bone
mass per year. This rate of bone loss is significantly
associated with the duration of the inflammatory bowel
disease. Therefore, the authors conclude that old age, low
BMI and long duration of inflammatory bowel disease can
be used to identify patients with PSC who might have the
most benefit from measurements of bone density and
treatments for bone diseases [22].
Finally, some recent data showing similar bone histo-
morphometric changes in PBC and PSC, suggest that both
decreased bone formation and increased resorption con-
tribute to bone disease in female patients with PBC and
PSC, whereas decreased bone formation rather than
increased resorption may be an important pathogenic
mechanism more relevant in male patients. These histo-
morphometric studies were performed in patients with
advanced PBC and PSC undergoing liver transplantation,
and thus further studies are necessary to determine whether
similar histomorphometric changes occur in patients with
earlier stages of liver disease [23].
Other chronic liver diseases
In non-cholestatic liver disorders, like hereditary hemo-
chromatosis and other more prevalent liver diseases, such
as cirrhosis, viral chronic hepatitis and alcoholic liver
disease, there is less information.
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Hereditary hemochromatosis
From available data, about 30% of patients with hereditary
hemochromatosis have osteoporosis. In a recent study of 87
patients (80% male) with hereditary hemochromatosis, a
quarter of them have osteoporosis and 41% have osteope-
nia, even in subjects without cirrhosis and hypogonadism.
In this disease, the deposits of iron deposits may be
responsible for low bone formation, due to the direct
lesion-producing effects of iron on osteoblast activity [24].
Cirrhosis
Several studies conducted over the past two decades
demonstrate that the prevalence of osteoporosis in patients
with liver cirrhosis, albeit with wide variability among the
studies, is around 33%, ranging from 20 to 100%, espe-
cially in patients with end-stage liver disease before
transplantation. These differences in prevalence reflect,
probably, differences in age, etiology and severity of liver
disease, nutritional status (expressed as BMI), and in the
hypogonadism status of studied patients. Liver cirrhosis
seems to increase the risk of fractures by about two times
[25].
Viral chronic hepatitis
Regarding viral chronic hepatitis, and its treatment with
ribavirin and interferon, there are conflicting results. A
small study assessing bone mass in chronic viral hepatitis,
mostly hepatitis C virus, have shown that non-cirrhotic
hepatitis C virus infected patients do not differ from con-
trols [26], whereas in another recent study, BMD was low
in patients with chronic non-cirrhotic hepatopathy, suffer-
ing from chronic viral infection by hepatitis C virus. The
study, however, has no control group, and there are no
details about alcoholic intake [27]. Ribavirin and interferon
therapy, used in the treatment of patients with HCV-related
chronic active hepatitis, may have possible negative effects
on BMD of these subjects, as initially shown in some
studies [28]; but it is not confirmed with a demonstrated
increase in BMD, shown in those patients who achieve a
sustained serologic response [29].
Alcoholic liver disease
Bone disease in alcoholic liver disease has depicted more
uniform results, since excess alcohol intake is a known
independent risk factor for osteoporosis. Reduction in the
grade of bone formation has been observed in alcoholic
patients by bone biopsies, with low serum levels of oste-
ocalcin during alcohol intake, which normalizes with
abstinence [30]. Some authors demonstrate that alcoholic
men, with or without mild liver disease, have significantly
lower lumbar BMD than controls, and 29% have osteo-
porosis. The study also reports the prevalence of radio-
logical vertebral fractures to be up to 36%. In this series,
a previous history of non-vertebral fractures is high, ribs
being a frequent location, since they occurred in 26% of
patients. The authors suggest that traumatic fractures may
account for a great proportion of fractures in the alcoholic
population, although a fragility component cannot be ruled
out. Most of the studies are focused on alcohol consump-
tion without considering the contribution of liver disease to
the fracture risk [31].
Liver transplant
Patients who undergo liver transplant show a post-trans-
plant high prevalence of osteoporosis and fractures. Oste-
oporosis has become a major cause of co-morbidity in
these patients, as their longtime survival is considerably
increased in recent years. After liver transplantation, there
seem to be two main phases in post-transplant bone dis-
ease: the early and the late post-transplantation periods.
Before liver transplantation, there is a low bone turnover
state, supported by histomorphometric analysis of bone
biopsies and biochemical parameters. Shortly after liver
transplantation, in the first 3 months, there is a significant
and quantitatively large increase in bone turnover, sub-
stantiated by histomorphometric data, and an early increase
in the biochemical markers of bone resorption that exceeds
bone formation markers. Taken together, the earliest period
of rapid bone loss and high rate of fractures is associated
with a high bone turnover, with an uncoupling of resorption
and formation. The normalization of liver function and a
superimposed effect of immunosuppressive therapy, reliant
on fairly high doses of glucocorticoids combined with
cyclosporin A or tacrolimus, with their systemic effects,
give rise to the picture during the early post-transplant
period. The second and late phase, which generally appears
6 months after transplantation, is characterized by an
increase in both histologic parameters and biochemical
markers of bone formation. At this time, bone loss at the
lumbar spine has stopped, and BMD has begun to increase
spontaneously. Similarly, there is an increase in the PTH
serum concentrations comparable to those of creatinine, as
well as an increase in circulating osteocalcin. This sec-
ondary hyperparathyroidism, likely related to the decline of
renal function, associated with cyclosporin A administra-
tion, may be a major contributor to the disorder of bone
remodeling. These features occur while patients are
maintained on cyclosporin A alone, or when combined
with a low glucocorticoids dose. Therefore, factors
involved in bone turnover in this second phase after
transplantation are the normalization of liver function, and
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the gradual reduction in glucocorticoids, which are
responsible for an increase in bone formation, as well as a
secondary hyperparathyroidism, related to cyclosporin A
administration [32].
In post-transplanted patients, there is a rapid bone loss
within the first 6 months after transplantation, being as high
as was pointed out to 6% in the lumbar spine at 3 months,
and a frequency of fragility fractures, from minor trauma or
apparently non-traumatic ones, both vertebral, symptomatic
or not, and non-vertebral, femoral and/or of extremities, of
about to 21%, most of which within first 2 years after
transplant, especially in women, female, elderly, chole-
static, and alcoholic patients, and particularly in those with
osteoporosis and fragility fractures before transplantation.
Most of post-transplant fractures, unlike pre-transplant
ones, seem to be symptomatic, and, most commonly, ver-
tebral, followed by ribs, with a minor prevalence of hip and
extremities, probably because predominantly cortical bone
sites are, in fact, less susceptible to osteoporotic fractures
when compared with trabecular ones [33]. An etiology of
this metabolic disorder is multifactorial, and risk factors
contributing to it are both pre-transplant and post-transplant
ones. Among pre-transplant risk factors, pre-transplant
fragility fracture is more predictive for post-transplant
recurrent fractures compared to the simple values of BMD.
However, BMD measurement, of course, is also crucial in
these patients, because low BMD values, before and after
transplant, are associated with a higher frequency of frac-
tures. In addition, there is widespread consensus on osteo-
porosis and fracture risk in post-transplant patients, as
determined by age ([45 years for women, [65 years for
men), gender (female, although some studies showed an
increased susceptibility to osteoporosis and fractures in
males patients), menopausal status (postmenopausal), type
of pre-transplant liver disease (increased risk for cholestatic
or alcohol related disorders,) and exposure to corticoste-
roids in the pre-transplant phase. Other possible pre-trans-
plant risk factors, for which there is no unanimous
consensus, in themselves considered as risk factors for post-
transplant osteoporosis and fractures, are 25-OHD and PTH
serum levels, bone turnover markers, and biochemical
parameters of liver (with reference also to the Child–Pugh
class of membership, with class C at greater risk of osteo-
porosis than class A) and kidney function. The most
important among post-transplant factors is represented by
acute osteopenia that occurs immediately after transplant,
with a significant decrease of BMD in first 3 months, and a
return to pre-transplant values only after about 2 years [34].
An important contributing cause of rapid bone loss in the
immediate postoperative period of these patients is proba-
bly the use of high doses of corticosteroids and other
immunosuppressive agents, such as cyclosporin A and ta-
crolimus, immobility and poor nutrition. Cumulative steroid
doses, administered in early post-transplant, and, in this
delicate phase, at particularly high dosage, has been
repeatedly implicated in pathogenesis of acute bone loss
observed in these patients, while current use of lower ste-
roids doses after transplant, as shorter time of hospitaliza-
tion and immobilization, explain the sharp reduction of
osteoporosis and fracture frequency in the post-transplant
patient reported in several studies. Contrariwise, the effects
of calcineurin inhibitors (i.e., tacrolimus), administered
after liver transplant as anti-rejection drugs, on bone turn-
over, via increased PTH serum levels from a decrease in the
glomerular filtration rate, are still under examination as it is
difficult to separate possible bone loss effects of these drugs
from those of corticosteroids used in anti-rejection treat-
ment regimens. However, it seems that patients treated with
tacrolimus have an earlier recovery of mineral content and
trabecular bone structure as compared to patients taking
cyclosporin A, but effects of both on bone loss in the early
post-transplant period remain unclear. Both, however, seem
to increase turnover and bone resorption, cyclosporin A,
perhaps, more than tacrolimus [35].
To our knowledge, there are no studies assessing bone
disease in liver transplant recipients under immunosup-
pressive agents, such as rapamycin, mycophenolatemofetil,
and daclizumab. Finally, post-transplant variables that do
not seem to have any effect on the prevalence of fractures
after intervention are waiting time before the procedure,
hospitalization length, immunosuppressive doses used, both
daily and cumulative, and episodes of organ rejection [36].
Measurement of BMD and diagnosis of osteoporosis
The presence of risk factors for the development of oste-
oporosis should be evaluated in patients with CLD,
including the following: advanced age, early menopause,
secondary amenorrhea of more than 6 months, male
hypogonadism, BMI lower than 19 kg/m2, chronic alcohol
intake, smoking, treatment with glucocorticoids (5 mg/day
of prednisone or over for more than 3 months), previous
fragility fractures, and family history of osteoporotic
fracture. Despite some differences, most of guidelines and
recommendations agree about DEXA determinations, as
routine screening test, in all CLD patients, especially if
major risk factors for osteoporosis can be evidenced,
especially and in patients affected with chronic cholestasis
and cirrhosis. Other possible indications to BMD mea-
surement are hereditary hemochromatosis, and postmeno-
pausal HCV? women, especially before IFN-based
therapy, before and after hepatic transplant, and before
steroids or cyclosporin A treatment. In all these cases, if an
osteoporosis osteopenic framework is diagnosed, a medical
treatment should be immediately started. BMD should be
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measured in patients with liver cirrhosis, both in biliary
(i.e., PBC and PSC) and in non-biliary one, before and after
hepatic transplant and before steroids or cyclosporin A
treatment. Indications to BMD measurement are less clear
in patients with cholestatic liver disease not waiting for
transplant. For example, the guidelines of the American
Gastroenterological Association suggest that BMD should
be measured in all patients with PBC at diagnosis time,
while others recommendations suggest BMD measurement
only in cholestatic patients with a bilirubin greater than
three times the upper limit of normal range. Unfortunately,
there is still no agreement about the frequency of BMD
measurements during the follow-up of patients. If no
osteoporosis has been diagnosed, but in the presence of risk
factors, there is probably no need to repeat BMD mea-
surement DEXA more often than once every 2–3 years.
Contrariwise, clinical conditions associated with a rapid
bone loss, such as in cholestatic patients (i.e., PBC and
PSC), with more than one risk factor for osteoporosis, and
in those recently initiating high-dose corticosteroid thera-
pies, the screening should be performed in a shorter time of
approximately every year. This schedule is also recom-
mended for cirrhotic patients with advanced clinical stage
and those potentially eligible for liver transplantation.
Considering then, that osteoporosis may also be the first
clinical manifestation of an underlying cholestatic liver
disease, it is advisable to screen for anti-mitochondrial
antibodies in all osteoporotic patients with a low BMD and
high cholestasis markers (gamma-glutamyltranspeptidase,
c-GT, and alkaline phosphatase) [37, 38]. Lateral X-rays of
the dorsal and lumbar spine should also be carried out to
reveal vertebral fractures. In addition, circulating serum
levels of calcium, phosphorous, 25-hydroxyvitamin D
25-OHD and PTH serum levels should be assessed. Dis-
turbances in thyroid and gonadal function should be ruled
out in particular cases. Individual response to anti-osteo-
porotic treatment can be monitored assessing biochemical
markers of bone turnover. However, there is not much
information on changes in bone markers in therapeutic
trials in patients with CLD, nor are there any practical
guidelines for their use in the clinical management of
postmenopausal osteoporosis. It seems they are not useful
neither to stratify fracture risk nor to assess deterioration of
bone health during follow-up. The indication of undercal-
cified transilial bone biopsy is advisable only if a miner-
alizing defect (i.e., osteomalacia) is suspected, which is, at
present, a very rare condition in CLD [37, 38].
Treatment of osteoporosis in chronic liver diseases
In all CLD patients, especially those with severe cholestasis
(bilirubin [30 for [6 months), the factors contributing to
bone loss should, as far as possible, be reduced to a mini-
mum, utilizing such basic preventive measures as stopping
alcohol intake and smoking. In general, physical activity
should be encouraged as much as possible, as specific
exercises aimed to improve the BMD and the mechanics of
the spine. However, the optimal exercise program for
osteoporosis in patients with CLD or after liver transplan-
tation has not yet been determined. Specific recommenda-
tions should be given in patients with increased risk of
falling. In addition, as a baseline prevention, an adequate
calcium/vitamin D intake (see below), by diet or pharma-
cological replacement, must be commenced by the patients.
Current recommendations suggest starting osteoporosis
treatment in all patients affected with CLD liver chronic
disease, especially if aged[65 years, or if 7.5 mg or more
of steroid drugs are required daily for more than 3 months,
although there is a possibility of an increased osteoporotic
risk for lower steroid doses as well. In younger patients,
suffering from CLD, treatment is indicated if BMD shows
T score values of -2.5. Likewise, it seems reasonable to
treat all patients as soon as possible after liver transplan-
tation, and before transplantation if they have osteoporosis.
Although serum and urine markers of bone turnover have
been used in the assessment and treatment monitoring of
patients affected with postmenopausal osteoporosis, there
are few studies about their use in osteoporotic patients with
CLD, and, actually, they should not be routinely obtained in
all patients. The treatment of osteoporosis in patients with
CLD is, essentially, based on the results of large trials
conducted in women with postmenopausal osteoporosis.
Contrariwise, there are, to date, only a few small studies
specifically conducted in patients with CLD, particularly
affected with PBC; ones, that, moreover, consider as pri-
mary outcome, the BMD increase rather than frequency
reduction of fragility fractures [39].
Diet, calcium and vitamin D
Whenever possible, a balanced diet should be prescribed,
since patients with advanced liver disease frequently have
little appetite and are malnourished. Supplements of cal-
cium (1,000–1,500 mg/day) and vitamin D (260 lg of
25-hydroxyvitamin D every 2 weeks, or vitamin D3 with a
dose of 400–800 IU/day or 5,000 IU/week, orally) should
be provided. However, there are very few studies on the
effectiveness of supplementation with calcium and vitamin
D, and as to their optimal dose and formulation in these
patients with CLD. Nevertheless, vitamin D deficiency
should be corrected to obtain a 25-OHD serum values of at
least 25–30 ng/mL. In patients with documented associated
malabsorption should use higher vitamin D doses. The
intestinal absorption of vitamin D may be reduced in
patients receiving resins, such as cholestyramine. The dose
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of glucocorticoids should be adjusted to the minimum
necessary [40].
Bisphosphonates
Bisphosphonates (alendronate, etidronate, ibandronate, and
risidronate), drugs act via inhibition of bone resorption
(Fig. 2), are all used in treatment of postmenopausal
osteoporosis, most often in combination with calcium and
vitamin D. Oral bisphosphonates are poorly absorbed in the
intestine; they are not metabolized and rapidly cleared from
the circulation. Approximately 50% of the absorbed frac-
tion concentrates in the skeleton, and the remainder is
excreted via the urine. There are, however, very few
studies about their use in patients with cirrhosis, especially
with PBC, so data about their safety and effectiveness are
still inadequate. Furthermore, the physician must evaluate
osteoporosis prevalence in patient-specific liver disease,
the need for treatment in the light of natural history of
disease in the single patient (life expectancy), and the
potential hepatotoxicity of the treatment, both drug-related
(consider hepatic and renal function) and unpredictable,
together with gastric mucosal problems (i.e., portal
hypertensive gastropathy) and varices. In patients with
PBC, alendronate, more than etidronate, seems to increase
bone mass and BMD, and improve markers of bone turn-
over, while it seems to show no reduction in fracture
incidence [41].
Arase et al. [42], retrospectively demonstrate, in post-
menopausal women with CLD and osteoporosis that cyclic
etidronate therapy within 3 months after osteoporosis
diagnosis significantly reduces the appearance of bone
fracture (4.9% in etidronate group and 13.8% in control no-
treated group, not given any drugs for osteoporosis after the
diagnosis). No complications from esophageal daily
administration of alendronate were observed, although
other studies, also conducted in patients affected with PBC,
suggest that alendronate is better tolerated when adminis-
tered once a week, rather than daily [43]. Preliminary
results comparing alendronate 70 mg weekly versus
ibandronate 150 mg monthly in PBC patients with osteo-
porosis or low bone mass and fragility fractures show that
both drugs have similar effects on BMD, but the adherence
to treatment is superior for monthly ibandronate, without
adverse effects on liver tests [44]. Contrariwise, Floreani
et al. conducted a prospective study on 100 post-meno-
pausal women, affected with PBC, treated with calcium
(1,000 mg/day), vitamin D3 (880 IU/day) and i.m. diso-
dium clodronate (100 mg, every 10 days) for 4 years. The
BMD was assessed by DEXA at the baseline and every
2 years for up to 4 years.
The treatment did not significantly improve osteoporosis
or osteopenia, but prevents the natural bone loss in these
patients [45]. In patients affected with non-biliary cirrhosis,
bisphosphonates seem, overall, well tolerated in weekly
administration, although they must be used with care in
patients with a recent history of bleeding or with esopha-
geal sclerotherapy, but these studies were carried out on
too small a series to make judgements about their effec-
tiveness in this different context [46]. Some small studies
in patients undergoing liver transplant have been conducted
to reduce the incidence of fractures after surgery, using
Fig. 2 Bisphosphonates
mechanism of action
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bisphosphonates. Most of them used intravenous pamidr-
onate, others alendronate (weekly administered) and
zoledronic acid, obtaining variable results, from a fracture
reduction to a BMD rising without change in the incidence
of fractures, to neither fracture reduction nor BMD rising.
Failure in protective effect detection of these drugs against
fracture, found in some of these studies, may reflect,
however, only the size of the evaluated sample, and an
inappropriate design to detect the capacity of reducing the
risk of new fractures, whereas an overall decrease of
fracture rate has been observed in post-transplant patients
in the last 20 years [5]. In this context, it is important to
take care of a particular side effect of bisphosphonate
therapy, which is osteonecrosis of the jaw. Most reported
cases involve oncologic patients treated with intravenous
pamidronate or zoledronic acid, but it has been reported
even in patients without cancer in oral treatment. About 2/3
of cases occur after tooth extraction. At date, there is not
any knowledge about relevance and prevalence of this
adverse reaction in patients with CLD [47].
Other treatments
Hormone replacement therapy
Hormone replacement therapy (HRT) is actually a second-
line choice therapy for osteoporosis treatment, due to evi-
dence of an increased risk of thromboembolic and gyne-
cologic malignant neoplasm. However, it may be
theoretically administered, especially in pre-menopausal
women with CLD and documented hypogonadism, or in
early menopause women (before 45 years) affected with
PBC or autoimmune cirrhosis, or, finally, in postmeno-
pausal women after liver transplantation, usually given by
the transdermal route, to increase BMD [48].
Raloxifene
Raloxifene is an estrogen receptor modulator, which has
also been shown to reduce the frequency of vertebral
fractures in women with postmenopausal osteoporosis.
Contrariwise, it does not seem to affect the frequency of
femoral fractures. Currently, there are few data on its safety
and efficacy in osteoporotic patients with CLD [49].
Strontium ranelate
In patients with postmenopausal osteoporosis, strontium
ranelate can be successfully used to reduce vertebral and
non-vertebral fracture. Its mechanism of action is not well
known, and, to date, there are no studies on its efficacy and
safety in patients with CLD, especially in those intolerant
to bisphosphonates ones [50].
Recombinant PTH
Recombinant PTH has been used for secondary prevention
of fragility fractures in women with postmenopausal oste-
oporosis, intolerant to bisphosphonate. It works by
increasing bone synthesis. To date, there are no studies on
its safety and efficacy in patients with CLD [51].
Conclusions and prospectives
Osteoporosis is the most important form of liver osteo-
dystrophy, especially in the end-stages and in cases with
chronic cholestasis, hereditary hemochromatosis and
alcohol abuse, often not clinically evident, and, therefore,
underdiagnosed. Despite a decline of the osteoporosis
incidence in the last 20 years in patients with end-stage
CLD, a large number of patients waiting for liver transplant
are affected with osteoporosis, and many of them have
already had fractures. It is important to identify these
individuals, because pre-transplant fractures increase the
risk of post-transplant ones, and because fractures, when-
ever they occur, are associated with great morbidity, even
in non-transplanted cirrhotic patients. The pathogenesis of
osteoporosis is mainly characterized by low bone forma-
tion, particularly related to the effect of retained substances
of cholestasis, such as bilirubin and bile acids, or to the iron
and alcohol on osteoblastic cells. Increased bone resorption
has also been described, especially in cholestatic women
with advanced disease. Good nutrition, such as suppression
of risk factors, and the administration of supplements of
calcium and vitamin D, is strongly recommended for the
prevention and treatment of osteoporosis. Evidence of
beneficial effects of pharmacological treatment in these
particular groups of patients is still, mainly, based on
studies conducted in women with postmenopausal osteo-
porosis, being few in number and with small numbers of
subjects in studies on patients with CLD. In particular,
bisphosphonates, especially weekly alendronate and
monthly ibandronate, appear to improve BMD, and to be
well tolerated, but studies in this regard are too small to
show a real beneficial effect, even on fracture frequency.
The efficacy of bisphosphonates in patients after liver
transplantation remains to be confirmed, although appeal-
ing effects of pamidronate, alendronate and zoledronic acid
have been reported. The outcome in reducing the incidence
of fractures has not been adequately demonstrated essen-
tially because of the low number of patients included in the
therapeutic trials.
In conclusion, in all CLD patients, especially those with
severe cholestasis, and in the presence of a normal BMD,
basic preventive measures must be considered (i.e., avoid-
ing excess alcohol intake, smoking cessation, regular
386 Intern Emerg Med (2013) 8:377–388
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weight-hearing exercise, and adequate calcium/vitamin D
intake, by diet or pharmacological replacement). In this
context, physicians must also consider hypogonadism cor-
rection, and to repeat DEXA in 2–3 years. If on long-term
corticosteroids treatment, minimize the dose, and repeat
DEXA in 1 year. If osteopenic, basic preventive measures
must be applied plus repeat DEXA in 2–3 years. If on long-
term corticosteroid therapy, consider bisphosphonates and
repeat DEXA in 1 year. Finally, if CLD patient is osteo-
porotic, basic preventive measures must be applied, plus
screening for other low BMD causes (i.e., laboratory screen:
complete blood count, serum creatinine, serum calcium,
serum phosphate, alkaline phosphatase, protein electro-
phoresis, 25-OHD, PTH, thyroid function tests, oestradiol,
FSH, LH, and testosterone [in men]), bisphosphonate
therapy and repeat DEXA in 1 year. 25
Box
Box 1: Among patients with chronic liver disease, who
should undergo bone mineral density measurement?
• Cholestatic (primary biliary cirrhosis/primary scleros-
ing cholangitis)
• Hereditary hemochromatosis
• Selected viral (postmenopausal HCV? patients)
• Before IFN-based therapy, if risk factors are present
• Alcohol
• Liver transplantation
• Before steroids and/or cyclosporin A
Box 2: When should bone mineral density be followed
after initial diagnosis
• If abnormal
• If cholestatic
• If on osteopenia inducing drugs
• Every 2–3 years, or every year in high-risk patients
(i.e., cholestatic ones)
Box 3: Use of bisphosphonates in patients with chronic
liver disease (cirrhosis)
• Size of the problem (prevalence of osteoporosis)
• Need for treatment in the light of natural history (life
expectancy)
• Safety of bisphosphonates:
• potential for hepatotoxicity
• drugs-related (consider hepatic and renal function)
• unpredictable
• gastric mucosal problems (portal hypertensive gastrop-
athy) and varices
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